【US Stock Movement】Seaport Therapeutics surged on September 30: Buy Rating + GlyphAllo

Seaport Therapeutics September 30 Surge Analysis

Keywords: Buy Rating, GlyphAllo

1. On September 25, Raymond James initiated coverage on Seaport Therapeutics with a “Strong Buy” rating; data from the same period show that the institutional average rating is “Buy,” with an average target price of $38.29.

2. On September 9, the company announced positive top-line results from the Phase I driving simulation study in healthy volunteers for GlyphAllo: after multiple 375 mg doses, there was no impairment in next-day driving performance, and a single 250 mg dose also met key secondary endpoints, with no serious adverse events reported; the company intends to submit these results to the U.S. Food and Drug Administration, and GlyphAllo is currently undergoing a Phase IIb BUOY-1 trial for the treatment of major depressive disorder.

(Disclaimer: This content is collected and summarized by AI technology based on public information, and is for reference only. It does not constitute investment advice.)